← Human Trials & Peer-Reviewed Studies
Predictors of discordance between physicians' and patients' appraisals of health-related quality of life in atrial fibrillation patients: findings from the Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial.
Plain-language guide to PMID 24016511 (2013): randomized controlled trial of Angiotensin Receptor Antagonists in 334 patients.
Key Facts
- PMID
- 24016511
- Journal
- American heart journal
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- von Eisenhart Rothe A et al. (6 authors)
- DOI
- 10.1016/j.ahj.2013.05.020
- Registered trial
- NCT00098137
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin Receptor Antagonists, published as a randomized controlled trial.
Assessing health status is fundamental when weighing treatment options for atrial fibrillation (AF) patients.
Most health-related quality-of-life (HRQoL) data stem from self-ratings, whereas treatment decisions are based upon physicians' estimations.
Who Took Part
According to the abstract, 334 patients were involved.
PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
The degree of congruence between patients' and physicians' assessments of the patients' subjective health status was used as an indicator of good communication and shared understanding.
How the Study Was Run
The design is described as randomized.
The patients were allocated by chance, so the Angiotensin Receptor Antagonists group and the comparison group should start out alike.
The Short Form-12 was used for self-ratings; the Short Form-8, for physician ratings.
What Was Measured
Assessing health status is fundamental when weighing treatment options for atrial fibrillation (AF) patients.
PubMed files the paper under topics including Angiotensin Receptor Antagonists, Atrial Fibrillation, Depression, Germany, Health Status, Patients and Physician-Patient Relations.
What This Means in Plain Language
The paper is a randomized study of Angiotensin Receptor Antagonists in 334 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2013 (American heart journal), a journal based in United States.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.